Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Penn Microbiome Therapy
- Development stage
- Unknown
- Lead developer
- University of Pennsylvania
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Cell Therapies
- Administration
- Oral, Rectal
01
Overview
Penn Microbiome Therapy (PMT) is a specific fecal microbiota transplant (FMT) intervention developed and produced by the University of Pennsylvania. It involves the transfer of a diverse, healthy microbial community from screened donors to a recipient's gastrointestinal tract to restore microbial balance and diversity. The therapy is primarily investigated as a treatment for severe or recurrent *Clostridium difficile* infections (CDI) and as a strategy for the decolonization of multidrug-resistant organisms (MDRO). By reintroducing a complex population of commensal bacteria, PMT aims to outcompete pathogens through competitive exclusion and restore the intestinal environment to a state that prevents the overgrowth of antibiotic-resistant or pathogenic bacteria.
- Other names
- Fecal Microbiota TransplantFMT
Beyond the preview
Go deeper on Penn Microbiome Therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Penn Microbiome Therapy.